source
- WHO advises against GLP-1 obesity drugs for children under 10, limits use in teensThe World Health Organization issued guidance recommending that GLP-1 drugs not be used to treat obesity in children younger than ten years old. For adolescents aged 10 to 19, the WHO says these m…
- Novartis-partnered Matchpoint Therapeutics raises $150 million Series B to fund clinical entryMatchpoint Therapeutics, a biotech company working with Novartis, announced the close of a new financing round. The round raised $150 million in Series B funding. The capital will be used to advan…